Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial

• DOI: 10.1177/0004867417709357
• Publication Date: 2017-06-03T07:33:27Z
• Authors: Olivia M Dean; Buranee Kanchanat...; Melanie Ashton; Mohammadreza Mohebbi; Chee Hong Ng; Michael Maes; Lesley Berk; Atapol Sughondhab...; Sookjaroen Tangwo...; Ajeet B Singh; Helen McKenzie; Deidre J Smith; Gin S Malhi; Nathan Dowling; Michael Berk
• Keywords: Clinical Global Impression; Adjunctive treatment; Minocycline

Objective: Conventional antidepressant treatments result in symptom remission 30% of those treated for major depressive disorder, raising the need effective adjunctive therapies. Inflammation has an established role pathophysiology and minocycline been shown to modify immune-inflammatory processes also reduce oxidative stress promote neuronal growth. This double-blind, randomised, placebo-controlled trial examined (200 mg/day, addition treatment as usual) disorder. investigated 200 mg/day (in Methods: A total 71 adults with disorder ( Diagnostic Statistical Manual Mental Disorders–Fourth Edition) were randomised this 12-week trial. Outcome measures included Montgomery–Asberg Depression Rating Scale (primary outcome), Clinical Global Impression–Improvement Impression–Severity, Hamilton Anxiety Scale, Quality Life Enjoyment Satisfaction Questionnaire, Social Occupational Functioning Range Impaired Tool. The study was registered on Australian New Zealand Trials Register: www.anzctr.org.au , #ACTRN12612000283875. Results: Based mixed-methods repeated analysis variance at week 12, there no significant difference scores between groups. However, differences, favouring group 12 score – effect size (95% confidence interval) = −0.62 [−1.8, −0.3], p 0.02; Questionnaire (confidence −0.12 [0.0, 0.2], < 0.001; Tool 0.79 [−4.5, −1.4], 0.001. These effects remained follow-up (week 16), Patient Impression became significant, 0.57 [−1.7, −0.4], 0.017. Conclusion: While primary outcome not improvements other comprehensive clinical suggest that may be a useful adjunct improve global experience, functioning quality life people Further studies are warranted confirm potential accessible agent optimise outcomes.